{"entity":{"id":"nct06281847","kind":"trial","name":"An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia","aka":[],"tldr":"A phase 1/2 trial of CCTx-001 run by Advesya SAS, not yet recruiting.","summary":"An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia is a phase 1/2 interventional study registered as NCT06281847 by Advesya SAS, with 143 participants planned, started 2025-12. Conditions recorded: Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory. Interventions recorded: CCTx-001.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06281847","url":"https://clinicaltrials.gov/study/NCT06281847"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["cctx-001"],"companies":["advesya"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06281847","phase":"1/2","setting":"An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia","sponsor":"Advesya SAS","enrolled":143,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06281847/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"cctx-001","kind":"drug","name":"CCTx-001","route":"/drugs/cctx-001/"}],"company":[{"id":"advesya","kind":"company","name":"Advesya","route":"/companies/advesya/"}]}}